---
anonymous_label: OUT-45
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
output_sha256: f736cee779da2c710175a6ebcc77bd42f41e7b3ed9715e99d45f59cc0dfdf63d
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-45

### Recommendation: The Claim File Review

You should recommend the **Claim File Review**.

#### Reasoning
Your current situation is a "false positive" trap. The executive team sees strong financial signals (expansion bookings, shortened sales cycles) and high usage numbers (+39%). However, the underlying data suggests these are lagging indicators or vanity metrics:
1. **Financials are distorted:** Expansion is driven by temporary bundling/pricing incentives, not necessarily value realization.
2. **Usage is misleading:** The growth is driven by managers (training/auditing) rather than the end-users (adjusters).
3. **Retention is fragile:** Front-line adjusters are abandoning the tool after two days, and regional carriers are already planning to cut it.

The core problem is a **lack of evidence regarding "Job-to-be-Done" completion.** You do not know if SignalPath actually improves the claim outcome or if it is simply a "theatre of productivity" that managers like but adjusters find useless or risky (especially in regulated health-liability).

The other options fail to address this:
* **Scaling Broadly** is premature and risks a massive churn event in 12 months.
* **Usage Quality Sprint** measures *that* people are using it, but not *why* or if the output is correct. It tracks behavior, not value.
* **Commercial Cleanroom** tests price elasticity and sales narratives, but it doesn't fix the product. If the product is broken, a cleanroom just confirms you can't sell it without bribes; it doesn't tell you how to fix the workflow.
* **Narrowing to Health-Liability** is a premature pivot based on one segment's struggle, without knowing if the struggle is a solvable UX issue or a fundamental product failure.

The **Claim File Review** is the only option that provides "ground truth." By auditing actual files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (accepted vs. overridden suggestions). This tells you exactly where the product is failing: Is it a lack of trust? A lack of explainability? Or simply wrong advice?

#### The Tradeoffs
By choosing the Claim File Review, you are sacrificing **speed of commercial validation.** You are telling the CEO that you cannot yet guarantee the "expansion" trend is real or sustainable. You are effectively pausing the aggressive sales momentum to ensure you aren't building a "leaky bucket."

#### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. While you are spending weeks reviewing files, the sales team may lose momentum, and the board may perceive a "loss of confidence" in a feature that they currently believe is a home run. It is the least "exciting" option for an executive team riding a high from a strong quarter.

#### Observable Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "abandonment" by adjusters was not due to product failure, but due to a **lack of mandate.**

If the Claim File Review reveals that the suggestions are actually accurate and helpful, but adjusters simply aren't *required* to use them by their bosses, the problem is no longer a product/value problem—it is a pricing and packaging problem. In that case, you don't need to fix the software; you need to change how it is sold and positioned (the Cleanroom) to ensure it is tied to a corporate mandate rather than an adjuster's preference.
